Opus Genetics (IRD) Depreciation & Amortization (CF) (2010 - 2020)
Opus Genetics (IRD) posted quarterly Depreciation & Amortization (CF) of $13000.0 for Q1 2026, little changed year-over-year from $13000.0 in Q1 2025, and little changed quarter-over-quarter from $13000.0 in Q4 2025.
Powered by 
Analysis
Opus Genetics (IRD) Depreciation & Amortization (CF) (2010 - 2020) Analysis & Trends
Opus Genetics (IRD) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $13000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) changed 0.0% year-over-year to $13000.0; the TTM figure through Mar 2026 stood at $53000.0 (up 130.43% YoY), while the FY2025 annual figure was $53000.0, up 430.0% from the prior year.
- Depreciation & Amortization (CF) held at $13000.0 in Q1 2026 per IRD's latest filing, from $13000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $14000.0 in Q2 2025 and bottomed at $1000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $6142.9 across 5 years, with a median of $2000.0 in 2022.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) changed 0.0% — and 2024, when it surged 233.33%.
- Opus Genetics' Depreciation & Amortization (CF) stood at $1000.0 in 2022, then surged by 200.0% to $3000.0 in 2023, then soared by 233.33% to $10000.0 in 2024, then increased by 30.0% to $13000.0 in 2025, then changed by 0.0% to $13000.0 in 2026.
- Business Quant data shows IRD's Depreciation & Amortization (CF) at $13000.0 in Q1 2026, $13000.0 in Q4 2025, and $13000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | 8,555.00 |
| Jun 30, 2020 | 9,203.00 |
| Mar 31, 2020 | 9,255.00 |
| Dec 31, 2019 | 9,532.00 |
| Sep 30, 2019 | 9,383.00 |
| Jun 30, 2019 | 10,544.00 |
| Mar 31, 2019 | 11,533.00 |
| Dec 31, 2018 | 11,007.00 |
| Sep 30, 2018 | 10,016.00 |
| Jun 30, 2018 | 12,588.00 |
| Mar 31, 2018 | 14,600.00 |
| Dec 31, 2017 | 11,395.00 |
| Sep 30, 2017 | 11,013.00 |
| Jun 30, 2017 | 11,023.00 |
| Mar 31, 2017 | 8,927.00 |
| Dec 31, 2016 | 8,793.00 |
| Sep 30, 2016 | 9,070.00 |
| Jun 30, 2016 | 8,892.00 |
| Mar 31, 2016 | 6,161.00 |
| Dec 31, 2015 | 7,556.00 |